Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7391218 | 0.91 | ROCK2 (0.34) | ROCK2TAS1R3TAS1R1CYP17A1CYP3A4 | |
| SCHEMBL6434401 | 0.90 | TAS1R3 (0.42) | TAS1R3TAS1R1 | |
| SCHEMBL6437334 | 0.88 | ROCK2 (0.49) | ROCK2 | |
| SCHEMBL6432917 | 0.85 | TAS1R3 (0.37) | ROCK2TAS1R3TAS1R1CYP17A1CYP3A4 | |
| SCHEMBL6437619 | 0.81 | PTPRC (0.42) | — | |
| SCHEMBL6433230 | 0.79 | ROCK2 (0.41) | ROCK2 | |
| SCHEMBL6433843 | 0.79 | DGAT2 (0.41) | CYP17A1CYP3A4 | |
| SCHEMBL7370207 | 0.78 | CASP3 (0.46) | — | |
| Trifluoroacetic Acid SCHEMBL7368235 | 0.77 | CA2 (0.40) | — | |
| Trifluoroacetic Acid SCHEMBL7372438 | 0.76 | GRN (0.45) | GRNSORT1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1077945-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER (US) | 2003-01-08 | — | — | EP | disclosed |
| US-6093731-A | Isoquinolines | PFIZER INC. | 2000-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | GRN 87/4885SORT1 692/4885ROCK2 2546/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | GRN 87/4885SORT1 692/4885ROCK2 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.